Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT0253 in KRAS G12D Mutated Advanced Solid Tumors
NCT06797336Phase 1Recruiting
- Sponsor
- PAQ Therapeutics
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of PT0253 in solid tumor (5 arms), sponsored by PAQ Therapeutics. Primary endpoints: Dose-limiting Toxicities at Cycle 1, Treatment-Emergent Adverse Events up to 24 months and 1 more. Started Dec 2024; status: recruiting.
02
Drugs
PT0253
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06797336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06797336.